Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CDK12/CDK13 Inhibitor
YJZ5118 is a selective inhibitor of cyclin-dependent kinases 12 and 13 (CDK12/CDK13), demonstrating IC50 values of 39.5 nM and 26.4 nM, respectively. This compound suppresses the transcription of DNA damage response genes, induces DNA damage in tumor cells, and effectively inhibits cellular proliferation while triggering apoptosis. YJZ5118 specifically impedes RNA polymerase II Ser2 phosphorylation and enhances Akt pathway activity, exhibiting synergistic effects when combined with Akt inhibitors. It is a valuable research tool for studying various cancers, including prostate cancer. -
CDK4 Inhibitor
CDK4-IN-4 is a selective inhibitor of Cyclin-dependent kinase 4 (CDK4), with an IC50 value of less than 10 nM. This compound plays a critical role in cancer research by selectively interfering with cell cycle regulation, thus inhibiting the proliferation of cancer cells. CDK4-IN-4 is suitable for studies focusing on cell cycle dynamics and the therapeutic potential of CDK4 inhibition in various cancer models. -
CDK7 Inhibitor
CDK7-IN-5 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 100 nM. This compound exhibits significant anticancer activity, making it a valuable tool in cancer research. Its ability to modulate transcriptional regulation positions CDK7-IN-5 as a promising candidate for studies aimed at investigating novel therapeutic strategies for cancer treatment. -
CDK2 Inhibitor
Cdk2/Cyclin Inhibitory Peptide II is a specific inhibitor of cyclin-dependent kinase 2 (CDK2), primarily influencing cell cycle regulation. This peptide has demonstrated the ability to induce apoptosis in U2OS osteosarcoma cells in a dose-dependent manner. Its application in research includes investigations into cell cycle dynamics and therapeutic strategies for cancer treatment. -
CDK1 Inhibitor
CDK1-IN-7 is a potent inhibitor of Cyclin-dependent kinase 1 (CDK1). It effectively inhibits the proliferation and migration of colorectal cancer cell lines, including HCT116 and Lovo. This compound serves as a valuable tool for investigating the role of CDK1 in colorectal cancer research and therapeutic strategies. -
CDK2 Inhibitor
CDK2-IN-52 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), exhibiting an impressive DC50 value of 1-10 nM. This compound effectively induces cell cycle arrest and inhibits the proliferation of tumor cells, making it a valuable tool for studying CDK2-overexpressing malignancies such as breast and ovarian cancers. CDK2-IN-52 facilitates research into potential therapeutic strategies targeting CDK2 in cancer treatment. -
CDK2 Inhibitor
CDK2-IN-14 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), known for its potency in inhibiting cell cycle progression. This compound plays a significant role in cancer research, allowing for the exploration of CDK2's involvement in tumorigenesis and potential therapeutic interventions. CDK2-IN-14 is suitable for studies aimed at understanding the mechanisms of cell proliferation and offers potential insights into novel cancer treatment strategies. -
CDK4 Inhibitor
CDK4-IN-2 is a potent inhibitor of cyclin-dependent kinase 4 (CDK4) with a Ki and IC50 value of less than 10 nM. This compound effectively regulates cell cycle progression and is valuable in cancer research, particularly in studies focused on oncogenic signaling pathways and cell proliferation. It serves as a crucial tool for evaluating potential therapeutic strategies targeting CDK4 in various malignancies. -
CDK7 Inhibitor
CDK7-IN-29 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of 1.4 nM. This compound demonstrates oral bioavailability and favorable pharmacokinetic properties, making it suitable for in vivo studies. Its ability to inhibit CDK7 positions it as a valuable tool for investigating cellular processes related to transcription and cell cycle regulation, particularly in cancer research applications. -
CDK8 Inhibitor
CDK8-IN-9 is a potent type II cyclin-dependent kinase 8 (CDK8) inhibitor, exhibiting an IC50 value of 48.6 nM. This compound effectively inhibits tumor growth and serves as a valuable tool in colorectal cancer research. Its targeting of CDK8 makes it suitable for investigations into the molecular mechanisms underlying cancer progression and treatment responses. -
CDK2 Inhibitor
CDK2-IN-44 is a potent inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound effectively blocks the proliferation of cancer cells by inducing cell cycle arrest, promoting apoptosis, and triggering cellular senescence. CDK2-IN-44 is particularly relevant for research applications focused on ovarian and breast cancer, offering valuable insights into therapeutic strategies targeting CDK2 activity. -
CDK4/6 Inhibitor
CDK4/6-IN-13 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), pivotal regulators of the cell cycle. This compound demonstrates low nanomolar potency, exhibiting significant antiproliferative activity against various cancer cell lines. CDK4/6-IN-13 also offers favorable metabolic properties and pharmacokinetic profiles, making it a valuable tool for research in oncology and cell cycle regulation. -
CDK Inhibitor
Fovinaciclibum is a cyclin-dependent kinase (CDK) inhibitor that demonstrates significant antineoplastic activity. This compound is designed to selectively inhibit CDK enzymes, thereby disrupting cell cycle progression and promoting apoptosis in cancer cells. It is utilized in research focusing on tumor biology and therapeutic strategies for various malignancies. -
CDK1 Inhibitor
CDK1-IN-4 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), exhibiting IC50 values of 44.52 nM for CDK1, 624.93 nM for CDK2, and 135.22 nM for CDK5. This compound effectively disrupts the cell cycle, leading to inhibition of cancer cell proliferation. CDK1-IN-4 is suitable for research applications related to cancer biology and therapeutics targeting cell cycle regulation. -
CDK2 Inhibitor
CDK2-IN-27 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), demonstrating potent inhibition with IC50 values of less than 10 nM for the CDK2/cyclin E1 complex and 10-20 nM for the CDK2/cyclin B1 complex. This compound is crucial for studies focused on cell cycle regulation and cancer research, where CDK2 plays a significant role in cell proliferation. CDK2-IN-27 provides valuable insights into therapeutic strategies targeting CDK2 to halt tumor growth and enhance cancer treatment regimens. -
CDK inhibitor
(R)-DRF053 is a selective cyclin-dependent kinase (CDK) inhibitor that primarily targets Cdk5. This compound is known to enhance the formation of ductal precursor β cells, making it valuable for investigating pancreatic development and diabetes research. Additionally, (R)-DRF053 has been shown to inhibit Dil-ox-LDL uptake and reduce CD36 gene expression induced by advanced glycation end products (AGEs) in U937 cells, indicating its relevance in studies related to atherosclerosis and metabolic diseases. -
CDK Inhibitor
CCT68127 is a selective inhibitor of cyclin-dependent kinases (CDKs) that functions by disrupting cell cycle progression. This compound demonstrates significant anti-proliferative activity in various cancer cell lines, making it a valuable tool for cancer research. CCT68127 can be utilized to investigate CDK-related pathways and explore potential therapeutic strategies for malignancies. -
CDK Inhibitor
Olomoucine II is a potent inhibitor of cyclin-dependent kinases (CDKs), specifically exhibiting IC50 values of 0.06 µM for CDK9/cyclin T, 0.1 µM for CDK2/cyclin E, 0.45 µM for CDK7/cyclin H, 7.6 µM for CDK1/cyclin B, and 19.8 µM for CDK4/cyclin D1. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studies investigating cell cycle regulation and cancer biology. Its selectivity and efficacy position Olomoucine II as an important reagent for research applications aimed at understanding CDK-related pathways. -
CDK Inhibitor
CDK1/2/4-IN-2 is a selective inhibitor of cyclin-dependent kinases 1, 2, and 4. This compound demonstrates significant anti-proliferative effects, making it a valuable tool for investigating cell cycle regulation and cancer biology. It is suitable for use in preclinical studies aimed at exploring therapeutic strategies for various malignancies. -
PKMYT1 Inhibitor
PKMYT1-IN-7 is a potent inhibitor of PKMYT1, demonstrating IC50 values of 1.6 nM against PKMYT1 and 0.06 μM against pCDK1. This compound effectively inhibits the phosphorylation of CDK1 at threonine 14 and tyrosine 15, making it valuable for research into cell cycle regulation. PKMYT1-IN-7 has shown significant anticancer activity, supporting its application in cancer biology studies. -
CDK2 Inhibitor
CDK2-IN-39 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a crucial regulator of the cell cycle. This compound demonstrates significant activity in modulating CDK2-mediated phosphorylation, making it a valuable tool for studies on cell proliferation, cancer research, and cellular signaling pathways. CDK2-IN-39 can help elucidate the role of CDK2 in the progression of various cancers and may aid in the development of therapeutic strategies targeting cell cycle dysregulation. -
CDK2 Inhibitor
CDK2-IN-21 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2) with an IC50 of 0.24 µM. This compound demonstrates potent inhibitory activity, making it a valuable tool for cancer research. By targeting CDK2, CDK2-IN-21 can help elucidate the role of cell cycle regulation in tumorigenesis and facilitate the development of potential therapeutic strategies against cancer. -
CDK Inhibitor
ZK 304709 is a multi-target cyclin-dependent kinase (CDK) inhibitor that plays a critical role in cell cycle regulation. It effectively inhibits various CDKs, thereby preventing proliferation in cancer cells. This compound is valuable for studying mechanisms of cell cycle control and can aid in the development of novel therapeutic strategies against cancer. -
CDK9 Inhibitor
CDK9-IN-34 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) with an IC50 value of 0.25 μM. It demonstrates significant cytotoxic effects on cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 exhibits antiviral properties against coronavirus 229E, displaying an IC50 of 145.92 μM. This compound serves as a valuable tool for investigating the roles of CDK9 in cancer and viral pathogenesis. -
CDK7 Inhibitor
LDC4297 hydrochloride is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), exhibiting an IC50 of 0.13 nM. This compound effectively inhibits human cytomegalovirus (HCMV) replication with an EC50 value of 24.5 nM and demonstrates broad antiviral activity against multiple families of viruses, including Herpesviridae, Adenoviridae, Poxviridae, Retroviridae, and Orthomyxoviridae, with EC50 values ranging from 0.02 to 1.21 μM. LDC4297 hydrochloride is valuable for research into viral infections and the underlying mechanisms of CDK7 in cellular pathways. -
CDK9 Inhibitor
CDK9-IN-30 is a selective inhibitor of Cyclin-dependent kinase 9 (CDK9), primarily targeting its role in transcription regulation. This compound exhibits potent antiviral activity by disrupting HIV-1 replication, making it a valuable tool for studying HIV-1 pathogenesis and exploring therapeutic strategies. Its inhibition of CDK9 can also provide insights into broader cellular processes related to transcriptional regulation and oncogenesis. -
KRAS Inhibitor
KRAS-IN-56 is a selective KRAS inhibitor that targets the interaction between GTP-bound KRAS and SOS1, demonstrating an EC50 of 33 μM. This compound effectively reduces phosphorylated ERK (p-ERK) levels, making it a valuable tool for studying MAPK signaling pathways. KRAS-IN-56 is particularly relevant for research applications involving lung cancer and other KRAS-driven malignancies. -
PLK2 Inhibitor
Y207–5465 is a potent and highly selective inhibitor of Polo-like kinase 2 (PLK2), exhibiting an IC50 value of 584.3 nM. This compound demonstrates limited anti-cancer activity in human colorectal cancer cell lines HT-29 and HCT-116. It is suitable for use in cancer research, providing insights into the role of PLK2 in tumorigenesis and therapeutic resistance. -
PLK4 Inhibitor
Ocifisertib fumarate is a potent and selective inhibitor of Polo-like kinase 4 (PLK4), exhibiting a Ki value of 0.26 nM and an IC50 of 2.8 nM. This compound demonstrates significant biological activity in the modulation of cell cycle progression and centrosome duplication. Ocifisertib fumarate is primarily utilized in research focused on cancer biology, particularly in studies assessing the role of PLK4 in tumorigenesis and potential therapeutic interventions targeting this kinase. -
PLK1 Inhibitor
Plogosertib is a selective and potent ATP-competitive inhibitor of the polo-like kinase 1 (PLK1) with an IC50 of 3 nM. This compound exhibits significant anti-proliferative activity, making it a valuable agent in cancer research. Plogosertib is applicable in studies involving various malignancies, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers. -
PLK4 Inhibitor
RP-1664 is a selective and orally active inhibitor of Polo-like kinase 4 (PLK4) with an IC50 of 3 nM. This compound exhibits remarkable selectivity toward PLK4 compared to related kinases such as AURKA, AURKB, and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells, resulting in the accumulation of PLK4 and p21 proteins. Its anti-tumor activity has been demonstrated in models of breast cancer and neuroblastoma, particularly in TRIM37-high-expressing cellular contexts. -
PLK4 Inhibitor
PLK4-IN-4 is a potent inhibitor of polo-like kinase 4 (PLK4), demonstrating an IC50 value of 7.9 nM. This compound effectively disrupts PLK4 activity, a critical regulator of centriole duplication, making it a valuable tool for cancer research. PLK4-IN-4 is suitable for studies investigating the role of PLK4 in tumorigenesis and may aid in the development of targeted cancer therapies. -
PLK4 Inhibitor
PLK4-IN-1 is a selective inhibitor of PLK4, exhibiting an IC50 of less than or equal to 0.1 μM. This compound plays a critical role in cell cycle regulation through the inhibition of polo-like kinase 4 activity. Its application is significant in research focusing on cell proliferation, cancer therapeutics, and understanding mitotic processes. -
PLK1 Inhibitor
Cyclapolin 9 is a selective ATP-competitive inhibitor of polo-like kinase 1 (PLK1) with an IC50 of 500 nM. This compound demonstrates potent inhibition specifically against PLK1, making it a valuable tool for studying cell cycle regulation and cancer biology. Its selectivity and efficacy support research applications focused on tumorigenesis and targeted cancer therapies. -
PLK1 Inhibitor
Dihydrobaicalein is a selective PLK1 inhibitor, exhibiting an IC50 of 6.3 μM. This compound also demonstrates inhibitory activity against VRK2 and PLK2, making it a valuable tool in cancer research. Derived from the natural source Scutellaria scandens, dihydrobaicalein is utilized in studies exploring cell cycle regulation and mitotic processes. Its ability to modulate specific kinases positions it as a significant candidate for further investigation in therapeutic applications. -
PLK1 Inhibitor
PLK1-IN-11 is a selective inhibitor of Polo-like kinase 1 (PLK1), exhibiting an IC50 of 1 μM. This compound demonstrates significant potential for modulating cell proliferation and mitotic progression. PLK1-IN-11 is suitable for investigation in various cancer models, including pancreatic, ovarian, breast, and non-small cell lung carcinoma, contributing to the understanding of cancer biology and the development of targeted therapies. -
Plk Inhibitor
BTO-1 is a selective inhibitor of Polo-like kinase (Plk), a key regulator of the cell cycle. This compound is designed to interfere with Plk activity, impacting downstream phosphorylation and dephosphorylation processes. BTO-1 is utilized in research focused on cell cycle regulation, cancer biology, and the development of novel therapeutic strategies targeting Plk pathways. -
Polo-like Kinase (PLK) Inhibitor
DAP-81 is a potent inhibitor of Polo-like kinases (PLKs), a group of essential serine/threonine kinases involved in cell cycle regulation. This compound has been shown to dose-dependently increase the formation of monopolar spindles in treated cells, indicating its role in disrupting normal mitotic spindle assembly. High-resolution live-cell microscopy studies demonstrate that PLK activity is crucial for the integrity of bipolar mitotic spindles. By inhibiting PLK activity, DAP-81 destabilizes centromeric microtubules while enhancing the stability of other spindle microtubules, making it a valuable tool for researchers investigating cell division and potential anti-microtubule agents. -
PLK1/PRC1 Inhibitor
PLK1/PRC1-IN-1 is an inhibitor of the PLK1/PRC1 protein complex formation. This compound specifically targets the interaction between polo-like kinase 1 (PLK1) and protein-regulator of cytokinesis 1 (PRC1), disrupting their function. PLK1/PRC1-IN-1 is primarily utilized in research focused on non-small cell lung cancer (NSCLC) and provides insights into the mechanisms of cell division and tumor growth. -
PLK4 Inhibitor
CFI-400437 is an indolinone-derived, ATP-competitive inhibitor specifically targeting PLK4, exhibiting exceptional selectivity with an IC50 of 0.6 nM. This compound demonstrates potent inhibitory activity, making it a valuable tool for studying the role of PLK4 in cell cycle regulation and genomic stability. It is particularly useful in cancer research, where PLK4 dysregulation has been implicated in tumorigenesis. -
PLK4 Inhibitor
PLK4-IN-3 is a selective inhibitor targeting Polo-like kinase 4 (PLK4), exhibiting an IC50 value of 0.65 μM. This compound plays a critical role in disrupting cell division by modulating the function of PLK4, which is essential for cytokinesis and centriole biogenesis. PLK4-IN-3 is valuable in cancer research, particularly in studies investigating the proliferation and survival of cancer cells with dysregulated PLK4 activity. -
PLK1 Inhibitor
PLK1-IN-5 is a selective inhibitor of Polo-like Kinase 1 (PLK1), with an IC50 of less than 500 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for researchers studying cancer biology and therapeutic interventions. Its ability to effectively inhibit PLK1 offers potential applications in the development of novel cancer treatments. -
PLK1 Inhibitor
PLK1-IN-4 is a highly selective and potent inhibitor of Polo-like kinase 1 (PLK1), exhibiting an IC50 of less than 0.508 nM. It demonstrates significant antiproliferative effects across a range of cancer cell lines and induces mitotic arrest at the G2/M checkpoint, thereby promoting apoptotic pathways in cancer cells. This compound is valuable for investigations into hepatocellular carcinoma and other malignancies where PLK1 plays a critical role in cell cycle regulation. -
PLK Inhibitor
PLK1-IN-2 is a potent inhibitor of the polo-like kinase 1 (PLK1), exhibiting an IC50 value of 0.384 μM. This compound disrupts PLK1 activity, which is crucial for regulating cell division and cancer cell proliferation. It is primarily utilized in cancer research to investigate the role of PLK1 in tumorigenesis and to assess its potential as a therapeutic target. -
PLK1 Inhibitor
PLK1-IN-10 is a potent inhibitor of the polo-like kinase 1 (PLK1) polo-box domain. This compound disrupts the interaction between PLK1 and the cell division regulator protein PRC1, leading to a reduction in the expression of the CDK1-Cyclin B1 complex. Additionally, PLK1-IN-10 interacts with glutathione (GSH), increasing cellular oxidative stress and promoting apoptosis. Its applications include cancer research and studies on cell cycle regulation. -
PLK1 Inhibitor
TAK-960 monohydrochloride is a selective inhibitor of polo-like kinase 1 (PLK1), exhibiting an IC50 of 0.8 nM. It also demonstrates inhibitory effects on PLK2 and PLK3 with IC50 values of 16.9 nM and 50.2 nM, respectively. This compound effectively inhibits the proliferation of various cancer cell lines and shows significant antitumor activity in multiple tumor xenograft models, making it a valuable tool for cancer research applications. -
Plk1 Inhibitor
ZK-Thiazolidinone is a potent ATP-competitive inhibitor of Polo-like kinase 1 (Plk1), exhibiting an IC50 of 19 nM. It effectively inhibits tumor cell proliferation, induces cell cycle arrest, and causes characteristic mitotic defects. The compound disrupts the recruitment of γ-tubulin and Aurora A kinase to centrosomes, leading to compromised bipolar spindle maintenance and sister chromatid cohesion. ZK-Thiazolidinone is valuable for applications in cancer research. -
PLK1 Inhibitor
PLK1-IN-7 is a highly effective inhibitor of Polo-like kinase 1 (PLK1), demonstrating an IC50 of 0.66 nM. This compound exhibits significant antiproliferative and antitumor activities, making it a valuable tool for cancer research. Its ability to modulate PLK1 activity supports investigations into cell cycle regulation and potential therapeutic applications in oncology. -
PLK1 Inhibitor
IIP0943 is a potent and selective inhibitor of PLK1 (polo-like kinase 1), exhibiting an IC50 of 5.1 nM. This compound demonstrates significant antiproliferative activity against HCT116 cancer cells, with an IC50 of 0.22 µM. IIP0943 is a valuable tool for researchers investigating cancer therapeutics and the role of PLK1 in cell cycle regulation and tumor growth. -
Polo-like Kinase (PLK) Inhibitor
Poloxin-2 is a specific inhibitor of Polo-like Kinase 1 (PLK1), effectively inducing mitotic arrest in HeLa cells with an EC50 of approximately 15 μM. It targets the Polo-box domain to disrupt protein-protein interactions, facilitating its application in cancer research. The hydrophobic tag (HT) conjugated form, Poloxin-2HT, exhibits enhanced potency by promoting selective degradation of the PLK1 protein, resulting in increased apoptosis and reduced cell viability. This highlights the potential of hydrophobic tags as a novel strategy for targeting disease-associated proteins.
